about
Early development of the vertebrate inner earNoonan syndromeCombined targeting of BRAF and CRAF or BRAF and PI3K effector pathways is required for efficacy in NRAS mutant tumorsRAF kinase activity regulates neuroepithelial cell proliferation and neuronal progenitor cell differentiation during early inner ear development.C-Raf deficiency leads to hearing loss and increased noise susceptibility.Delphinidin attenuates neoplastic transformation in JB6 Cl41 mouse epidermal cells by blocking Raf/mitogen-activated protein kinase kinase/extracellular signal-regulated kinase signaling.Changed genome heterochromatinization upon prolonged activation of the Raf/ERK signaling pathway.Noonan syndrome: clinical aspects and molecular pathogenesis.Disorders of dysregulated signal traffic through the RAS-MAPK pathway: phenotypic spectrum and molecular mechanismsThe RalGEF-Ral Effector Signaling Network: The Road Less Traveled for Anti-Ras Drug Discovery.Sorafenib potently inhibits papillary thyroid carcinomas harboring RET/PTC1 rearrangement.Phospholipase D: enzymology, functionality, and chemical modulationApplication of a BRAF pyrosequencing assay for mutation detection and copy number analysis in malignant melanoma.Raf kinases: function, regulation and role in human cancer.Activated ERK2 is a monomer in vitro with or without divalent cations and when complexed to the cytoplasmic scaffold PEA-15.Mutant K-RAS Promotes Invasion and Metastasis in Pancreatic Cancer Through GTPase Signaling Pathways.Raf and MEK protein kinases are direct molecular targets for the chemopreventive effect of quercetin, a major flavonol in red wine.Constitutive activation of Raf-1 induces glioma formation in mice.BRAF(E600) in benign and malignant human tumours.Selective Raf inhibition in cancer therapy.Morelloflavone, a biflavonoid, inhibits tumor angiogenesis by targeting rho GTPases and extracellular signal-regulated kinase signaling pathways.Oncogenic B-RAF negatively regulates the tumor suppressor LKB1 to promote melanoma cell proliferation.The RAS/mitogen activated protein (MAP) kinase pathway in melanoma biology and therapeutics.How ERK1/2 activation controls cell proliferation and cell death: Is subcellular localization the answer?Deconstructing feedback-signaling networks to improve anticancer therapy with mTORC1 inhibitors.Targeting BRAF mutant metastatic colorectal cancer: clinical implications and emerging therapeutic strategies.Inter-cellular adhesion disruption and the RAS/RAF and beta-catenin signalling in lung cancer progression.MEK inhibitors in oncology: a patent review (2015-Present).Hepatitis B virus regulates Raf1 expression in HepG2.2.15 cells by enhancing its promoter activity.Biological effects of hexitol and altritol-modified siRNAs targeting B-Raf.Single substitution within the RKTR motif impairs kinase activity but promotes dimerization of RAF kinase.BAD contributes to RAF-mediated proliferation and cooperates with B-RAF-V600E in cancer signaling.Disposition of GDC-0879, a B-RAF kinase inhibitor in preclinical species.Dimerization of the kinase ARAF promotes MAPK pathway activation and cell migration.KIT and BRAF heterogeneous mutations in gastrointestinal stromal tumors after secondary imatinib resistance.PK-PD modeling of combination efficacy effect from administration of the MEK inhibitor GDC-0973 and PI3K inhibitor GDC-0941 in A2058 xenografts.Preclinical assessment of novel BRAF inhibitors: integrating pharmacokinetic-pharmacodynamic modelling in the drug discovery process.BRAF mutation status in gastrointestinal stromal tumors.Acquired resistance to BRAFi reverses senescence-like phenotype in mutant BRAF melanoma
P2860
Q26823188-401747BA-81E0-41CF-9ACE-2530172EAE88Q27001641-4CAE08D8-4DBE-47E9-B106-8C0CFDF44B69Q27349020-1BDFE95E-E36D-4638-9E97-2D2573FBB2ECQ30477716-A2DD4609-C66E-493B-9A2D-96B3F2F6CB12Q30664961-A554DDAE-A652-4FB2-80F6-41E7F2E3E48DQ33706073-BE0C014B-A4C2-4C1B-8F1B-0F9AA8D55C68Q33725691-5E65597E-9C71-4DFB-AA8E-E7F511C862E5Q33806161-9AC9015E-51D3-47D4-AC80-AF6C099187F1Q34440570-4A871354-0D9F-4061-90F4-B3C4BCEACA6DQ35083727-C8B7D57B-F8F2-4520-8D0A-B971D178D12DQ35570953-6A3350FE-D0FC-4A51-B2F2-2DFCBED77492Q35599714-9B16AC74-F42E-49D2-9781-3075A122D6DDQ35988122-3A3EAFA4-C04C-410B-ADA9-679D2A6BFEA5Q36002845-A51A63A3-DA39-4440-A232-245097C1F12BQ36107198-48E9B142-450F-4871-ABCA-DA9C1BE6569AQ36180749-9A28234B-0821-401B-BD6A-DD5AB945DF8AQ36512011-6E464BD1-B7CA-450C-AC20-32BB48F9C667Q36640215-98016B3C-D45A-4F6C-ABEC-653E53D7D503Q36921234-4A4F94A6-885D-4F74-BD43-371BFEC7BB66Q37004743-D9FA3398-7FDB-4EF6-98B1-AF5BCF32B6B8Q37142916-4F2D5841-DE7D-4A71-879F-94C800A4FFDCQ37274568-0983648F-11A6-4641-860B-6430BB3BC17BQ37290440-6EB276B2-70BB-4BE9-89A9-A48A4BF37DC5Q37309204-11FB0D43-B404-4ECC-B0CA-3D933049983BQ37355543-72CC8AD7-6F76-4FDA-9266-40E2978ACC69Q38239612-76A40D59-9F74-4657-8C5C-917C8531F2C3Q39134067-3B22BD49-D01A-412C-B1DB-1CAF2260F4C2Q39359514-003B7EFD-7870-4941-8B82-AB9EAEF13A90Q39612071-34E319A8-655A-4485-A60A-0016A9AC0BCFQ39859749-FFF8A353-D2CD-4F21-8BC3-E6EED6FD563BQ41908921-2A6234BD-7C76-46B6-BDCB-C9FB909DF8BBQ41983817-B9B3CCB4-AA43-4692-B2A0-09A4618E2FABQ45954926-70456D42-C9A1-47B9-BBAF-4596244202DDQ50643518-07C0A9FE-8642-4115-83F8-9D7BFF82B587Q54325449-5775F6C8-6337-403E-BE85-B3BBFA8718B1Q54478528-8BB78B26-439A-4AA2-A5F9-3E366D150476Q54565907-B8EC59C1-F0AF-4C0D-B008-ACDE65706749Q54702771-5C5C4CFC-67CC-4884-953E-D308840B6015Q58796907-4CA2915C-6B7E-47DA-83C3-C219DF2DE434
P2860
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Raf kinases: oncogenesis and drug discovery.
@ast
Raf kinases: oncogenesis and drug discovery.
@en
type
label
Raf kinases: oncogenesis and drug discovery.
@ast
Raf kinases: oncogenesis and drug discovery.
@en
prefLabel
Raf kinases: oncogenesis and drug discovery.
@ast
Raf kinases: oncogenesis and drug discovery.
@en
P2860
P356
P1476
Raf kinases: oncogenesis and drug discovery.
@en
P2093
Ralf Schreck
Ulf R Rapp
P2860
P304
P356
10.1002/IJC.22144
P577
2006-11-01T00:00:00Z